LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development

MGC Pharmaceuticals Ltd, a European based pharmaceutical company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration granted Orphan Drug Designation

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease of its novel solution Ensifentrine in mainland China.

Torrent Pharma has begun shipping the generic version of Xeris's Keveyis®, 50mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

SciSparc Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has been granted final approval from the Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, required to commence the Company’s Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome

Dipharma Francis S.r.l., a global CDMO and leading manufacturer of New Chemical Entities (NCE), Generic Active Pharmaceutical Ingredients and advanced Intermediates, announced today the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced interim data demonstrating the potential of CPI-818, the Company’s ITK inhibitor, for the treatment of T cell lymphoma (TCL) at the 10th Whistler Global Summit on Hematologic Malignancies, which took place March 29 to April 2, 2023 in Whistler British Columbia, Canada

Genenta Science, a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the license agreement with Ospedale San Raffaele (OSR) has been amended and restated to provide access to all solid tumor indications

REGiMMUNE Limited, a biotechnology company focused on developing innovative immunotherapies for immune disorders and cancer, and San Fu Biotech, a subsidiary of San Fu